8 completed, 7 recruiting, 2 active not recruiting, 2 terminated. 24 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 8, Recruiting 7, Active not recruiting 2, Terminated 2, Unknown 2, Withdrawn 2, Suspended 1 |
| Phase 1 | 2 | Completed 2 |
Follow 68Ga-PSMA: new trials by email Literature Review of 68Ga-PSMA trials Research Report on 68Ga-PSMA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11 - WHO Grade 3 Glioma, WHO Grade 4 Glioma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2026-01-12 | 2026-06-22 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
| Preoperative Planning With PSMA-PET in Melanoma Surgery Trial 68Ga-PSMA - Malignant Melanoma | Phase 2 | Recruiting | Royal Marsden NHS Foundation Trust | 16 | 2025-03-11 | 2025-07-01 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma Computed Tomography, Electronic Health Record Review, Ga-68 PSMA-11 - Metastatic Adenoid Cystic Carcinoma | Phase 2 | Completed | Mayo Clinic | 6 | 2024-08-12 | 2025-09-12 |
| Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 40 | 2024-08-01 | 2026-03-13 |
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan - Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 90 | 2024-08-01 | 2026-03-10 |
| Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Clinical Observation - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Suspended | Mayo Clinic | 236 | 2024-05-03 | 2026-08-20 |
| Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial Apalutamide, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 95 | 2024-03-28 | 2026-07-17 |
| Gallium-68 PSMA-11 PET in Participants With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-09-26 | 2024-03-07 | |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Completed | Mayo Clinic | 26 | 2022-01-30 | 2026-09-29 |
| 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 22 | 2021-06-16 | 2022-10-21 |
| An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | University of Washington | 141 | 2021-05-17 | 2026-01-09 |
| 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging - Hepatocellular Carcinoma | Phase 2 | Completed | Mayo Clinic | 52 | 2021-02-24 | 2026-08-12 |
| 68 Ga-PSMA for High Risk Prostate Cancer 68Ga-PSMA - Prostate Cancer, High Risk | Phase 1 / Phase 2 | Completed | The Methodist Hospital Research Institute | 80 | 2020-10-13 | 2023-08-28 |
| PET/MRI to Stage Prostate Cancer Patients 68Ga-PSMA, 68Ga-RM2 - Prostate Cancer | Phase 2 | Unknown | IRCCS San Raffaele | 50 | 2020-09-09 | 2024-07-03 |
| PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study 68Ga-PSMA, 68Ga-RM2 - Prostate Cancer | Phase 2 | Completed | IRCCS San Raffaele | 60 | 2020-06-03 | 2023-04-10 |
| Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11 - Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Emory University | 140 | 2019-05-10 | 2026-09-02 |
| Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer 68Ga-PSMA - Prostate Cancer | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 11 | 2018-11-13 | 2022-01-05 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 937 | 2018-04-02 | 2021-09-30 |
Showing 20 of 24. Sign in to see all of them.
Prostatic Neoplasms (17) · Carcinoma, Hepatocellular (2) · Carcinoma, Adenoid Cystic (1) · Melanoma (1)
Jonsson Comprehensive Cancer Center (6) · Mayo Clinic (5) · IRCCS San Raffaele (2) · Ebrahim Delpassand (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · German Cancer Research Center (1) · Jules Bordet Institute (1) · M.D. Anderson Cancer Center (1) · Royal Marsden NHS Foundation Trust (1) · The Methodist Hospital Research Institute (1) · University of Michigan (1) · University of Michigan Rogel Cancer Center (1) · University of Washington (1)
United States (18) · Italy (2) · Austria (1) · Germany (1) · United Kingdom (1)
Amar Kishan (2) · Brian J. Burkett, MD, MPH (2) · Jeremie Calais (2) · Jeremie Calais, MD (2) · Morand R Piert, M.D. (2) · Ajit H. Goenka, M.D. (1) · Ashesh Jani, MD, MSEE (1) · Brian Miles, MD (1) · Carlos Artigas, MD (1) · Delphine L. Chen, M.D. (1) · Frederik Giesel, Prof. Dr. (1) · Gregory C Ravizzini, MD (1) · Matthew P. Thorpe, M.D., Ph.D. (1) · Michael Schweizer (1) · Myles Smith (1)
PMID 33602654, PMID 34326126, PMID 34783177, PMID 39420060, PMID 40876952, PMID 41679923, PMID 41698328, PMID 42377125
P30CA138292 (1), R01CA226992 (1), R37CA286450 (1)